ANTIBODY-DEPENDENT ENHANCEMENT OF INFECTION AND THE PATHOGENESIS OF VIRAL DISEASE

被引:241
作者
MORENS, DM
机构
[1] UNIV HAWAII, SCH MED, DEPT TROP MED, HONOLULU, HI USA
[2] UNIV HAWAII, SCH PUBL HLTH, DEPT PUBL HLTH SCI, EPIDEMIOL SECT, HONOLULU, HI 96822 USA
[3] PACIFIC BIOMED RES CTR, HONOLULU, HI USA
关键词
D O I
10.1093/clinids/19.3.500
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody-dependent enhancement of infection (ADE) is an in vitro serological phenomenon -or a group of phenomena-in which viral infection of susceptible cells is modified by the addition of virus-reactive antibody. Evidence suggests that ADE reflects immunologic processes that occur in vivo. Various severe and even fatal viral conditions of humans and animals, including dengue shock syndrome, the ''early-death phenomenon'' in experimental infections of immune animals, and other vaccine- and immunoglobulin-modified conditions, have been attributed to ADE by some researchers. ADE has caused great concern in relation to the development of vaccines against dengue virus and human immunodeficiency virus. More data are urgently needed on the mechanisms and determinants of ADE and on its alleged role in disease pathogenesis and in vaccine-associated phenomena.
引用
收藏
页码:500 / 512
页数:13
相关论文
共 127 条
[11]  
CARDAMITIS J. P., 1929, Bulletin de la Societe de Pathologie Exotique, V22, P272
[12]  
Charles T Edmondston, 1872, Ind Med Gaz, V7, P121
[13]  
Charles T Edmondston, 1872, Ind Med Gaz, V7, P97
[14]  
Charles T Edmondston, 1872, Ind Med Gaz, V7, P73
[15]  
Charles T Edmondston, 1872, Ind Med Gaz, V7, P49
[16]  
Charles T Edmondston, 1872, Ind Med Gaz, V7, P25
[17]  
CHEW A, 1961, LANCET, V1, P307
[18]   FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION [J].
CHIN, J ;
MAGOFFIN, RL ;
SHEARER, LA ;
SCHIEBLE, JH ;
LENNETTE, EH .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) :449-+
[19]  
COPANARIS Phocion, 1928, Bulletin de l'Office International d'Hygiene Publique, V20, P1590
[20]   THE SAFETY AND IMMUNOGENICITY OF A HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RECOMBINANT GP160 CANDIDATE VACCINE IN HUMANS [J].
DOLIN, R ;
GRAHAM, BS ;
GREENBERG, SB ;
TACKET, CO ;
BELSHE, RB ;
MIDTHUN, K ;
CLEMENTS, ML ;
GORSE, GJ ;
HORGAN, BW ;
ATMAR, RL ;
KARZON, DT ;
BONNEZ, W ;
FERNIE, BF ;
MONTEFIORI, DC ;
STABLEIN, DM ;
SMITH, GE ;
KOFF, WC .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (02) :119-127